{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:57:08Z","timestamp":1790575028819,"version":"4.1.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adoptive T-cell and natural killer (NK)-cell therapies are expanding across solid tumors, but their registered development in gynecologic malignancies remains difficult to interpret because many studies use basket designs and registry records vary in detail.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional analysis of therapeutic adoptive T-cell and NK-cell trial records identified from TrialTrove, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform. Trials were classified into three mutually exclusive evidence-specificity groups: single gynecologic disease family specific, multiple gynecologic disease families only, and broader baskets including non-gynecologic cancers. We evaluated source sensitivity, target applicability, field-specific registry visibility, and the availability of posted registry safety results. A complementary registry-informed exploratory survey of 25 experts assessed translational barriers and development priorities using domain-specific 1\u20135 scales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 442 unique records screened, 211 therapeutic trials met the eligibility criteria. Of these, 43 were restricted to a single gynecologic disease family, 2 included multiple gynecologic disease families only, and 166 were broader basket trials permitting enrollment of non-gynecologic malignancies. The public-registry-linked and public-search-captured sensitivity subsets included 200 and 141 records, respectively, with broadly similar structural patterns across datasets. The landscape was predominantly early phase, with 149 Phase I and 50 Phase I\/II trials. CAR-T, TIL, and TCR-T were the leading modalities, accounting for 79, 60, and 42 trials, respectively. Only 20 records had posted registry results with an adverse-event module, indicating limited availability of registry-reported safety data. In the exploratory expert survey, an immunosuppressive tumor microenvironment and a lack of gynecologic-specific cohorts were identified as leading barriers, whereas ovarian cancer, TIL therapy, MSLN, target reporting, and registry completeness emerged as prominent development priorities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Registered cellular-therapy activity in gynecologic malignancies is broad but remains early phase, largely basket-derived, and unevenly visible in registry fields. Separating disease-specific trials from broader eligibility-only baskets, testing source sensitivity, and distinguishing modality biology from missing target reporting provide a more reproducible basis for future trial planning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1936815","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:44:06Z","timestamp":1790574246000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical trial landscape and translational priorities for adoptive T-cell and NK-cell therapies in gynecologic malignancies"],"prefix":"10.3389","volume":"17","author":[{"given":"Qingyu","family":"Chen","sequence":"first","affiliation":[{"name":"The Second School of Medicine, Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Zhu","sequence":"additional","affiliation":[{"name":"The Second School of Medicine, Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilin","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyi","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Life Sciences, Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41572-026-00686-x","article-title":"Ovarian cancer","volume":"12","author":"Scott","year":"2026","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cac2.12629","article-title":"Advances in cervical cancer: Current insights and future directions","volume":"45","author":"Xu","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2026.2248","article-title":"Endometrial cancer: A review","volume":"335","author":"Mager","year":"2026","journal-title":"Jama"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: Overall survival and exploratory analyses of the Nrg Gy018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (Engot-Cx11\/Gog-3047\/Keynote-A18): A randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2025.03.054","article-title":"T cell-based cancer immunotherapy: Opportunities and challenges","volume":"70","author":"Ma","year":"2025","journal-title":"Sci Bull (Beijing)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of Car-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70120","article-title":"Challenges and solutions to implementation of chimeric antigen receptor therapies in acute myeloid leukemia","volume":"116","author":"Maheswaran","year":"2026","journal-title":"Eur J Haematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"Car-T cell therapy for cancer: Current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"Car-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.ccell.2025.09.013","article-title":"Engineered natural killer cells for cancer therapy","volume":"43","author":"Biederst\u00e4dt","year":"2025","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02629-5","article-title":"Engineering innate immune cells for cancer immunotherapy","volume":"43","author":"Tarannum","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","article-title":"Engineered T cell therapy for viral and non-viral epithelial cancers","volume":"41","author":"Norberg","year":"2023","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: A first-in-human, phase I\/Ii study","volume":"37","author":"Doran","year":"2019","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2026.101028","article-title":"Current state of Car-T cell therapies for solid tumors","volume":"7","author":"Rosa","year":"2026","journal-title":"Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.08.009","article-title":"Overcoming solid-tumor barriers: Armored Car-T cell therapy","volume":"11","author":"Kwon","year":"2025","journal-title":"Trends Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"Car-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02446-2","article-title":"Beyond the blood: Expanding Car T cell therapy to solid tumors","volume":"43","author":"Uslu","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo Car engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (Car)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00832-9","article-title":"Regulatory T cells in the tumour microenvironment","volume":"25","author":"Imianowski","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2025.02.026","article-title":"Distinct Cd8(+) T cell dynamics associate with response to neoadjuvant cancer immunotherapies","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-24-0894","article-title":"T-cell senescence in the tumor microenvironment","volume":"13","author":"Huang","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084727","article-title":"The quality of registration of clinical trials: Still a problem","volume":"9","author":"Viergever","year":"2014","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)33220-9","article-title":"Compliance with legal requirement to report clinical trial results on Clinicaltrials.Gov: A cohort study","volume":"395","author":"DeVito","year":"2020","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMsr1611785","article-title":"Trial reporting in Clinicaltrials.Gov - the final rule","volume":"375","author":"Zarin","year":"2016","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in Car T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"Car T cell therapy for solid tumors: Bright future or dark reality","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of Car Nk cells","volume":"14","author":"J\u00f8rgensen","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"Car-Nk cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.aak9510","article-title":"Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer","volume":"356","author":"Stevanovi\u0107","year":"2017","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","article-title":"Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: A phase 2 trial","volume":"31","author":"Lowery","year":"2025","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1574742","article-title":"Car-Nk cell therapy: Promise and challenges in solid tumors","volume":"16","author":"Balkhi","year":"2025","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant Kras in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with Ny-Eso-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3910","article-title":"Ny-Eso-1-specific Tcr-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured Gpc3 Car T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1126\/science.adv7378","article-title":"Sensitive Car T cells redefine targetable Cd70 expression in solid tumors","volume":"391","author":"Hanina","year":"2026","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03650-6","article-title":"Autologous T cell therapy for Prame(+) advanced solid tumors in Hla-a*02(+) patients: A phase 1 trial","volume":"31","author":"Wermke","year":"2025","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00167-6","article-title":"Esgo-Estro-Esp guidelines for the management of patients with endometrial carcinoma: Update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02699-0","article-title":"Recent advances in immunotherapy for cervical cancer","volume":"30","author":"Ogasawara","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (Time) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13046-025-03432-5","article-title":"Deciphering the tumor immune microenvironment: Single-cell and spatial transcriptomic insights into cervical cancer fibroblasts","volume":"44","author":"Lin","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ccell.2025.12.021","article-title":"Armored macrophage-targeted car-t cells reset and reprogram the tumor microenvironment and control metastatic cancer growth","volume":"44","author":"Mateus-Tique","year":"2026","journal-title":"Cancer Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00753","article-title":"Expanding the therapeutic reach of chimeric antigen receptor t-cells and bispecific t-cell engagers across solid tumors","volume":"9","author":"Gerber","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5412","article-title":"Second primary cancer after chimeric antigen receptor-t-cell therapy: A review","volume":"11","author":"Patel","year":"2025","journal-title":"JAMA Oncol"},{"key":"B56","unstructured":"FDA requires boxed warning for T cell Malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor T-cell immunotherapies\n          \n          \n          \n          2024"},{"key":"B57","unstructured":"TECELRA (afamitresgene autoleucel) prescribing information\n          \n          \n          \n          2026"},{"key":"B58","unstructured":"AMTAGVI (lifileucel) prescribing information\n          \n          \n          \n          2024"},{"key":"B59","unstructured":"FDA eliminates Risk Evaluation and Mitigation Strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies\n          \n          \n          \n          2025"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081660","article-title":"Spirit 2025 explanation and elaboration: Updated guideline for protocols of randomised trials","volume":"389","author":"Hr\u00f3bjartsson","year":"2025","journal-title":"Bmj"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081477","article-title":"Spirit 2025 statement: Updated guideline for protocols of randomised trials","volume":"389","author":"Chan","year":"2025","journal-title":"Bmj"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified t cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-10-0192","article-title":"Successful eradication of established peritoneal ovarian tumors in scid-beige mice following adoptive transfer of t cells genetically targeted to the muc16 antigen","volume":"16","author":"Chekmasova","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-157","article-title":"A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous t cells for recurrent ovarian cancer","volume":"10","author":"Kandalaft","year":"2012","journal-title":"J Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1936815\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:44:07Z","timestamp":1790574247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1936815\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2026.1936815"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1936815","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1936815"}}